par Richard, François;Majjaj, Samira 
;Venet, David ;Rothé, Françoise ;Pingitore, Julien;Boeckx, Bram;Marchio, Caterina;Clatot, Florian;Bertucci, François;Mariani, Odette;Galant, Christine;Eynden, Gert van den;Salgado, Roberto;Biganzoli, Elia;Lambrechts, Diether;Vincent-Salomon, Anne;Pruneri, Giancarlo;Larsimont, Denis ;Sotiriou, Christos ;Desmedt, Christine
Référence Clinical cancer research, 26, 23, page (6254-6265)
Publication Publié, 2020-12-01
;Venet, David ;Rothé, Françoise ;Pingitore, Julien;Boeckx, Bram;Marchio, Caterina;Clatot, Florian;Bertucci, François;Mariani, Odette;Galant, Christine;Eynden, Gert van den;Salgado, Roberto;Biganzoli, Elia;Lambrechts, Diether;Vincent-Salomon, Anne;Pruneri, Giancarlo;Larsimont, Denis ;Sotiriou, Christos ;Desmedt, Christine Référence Clinical cancer research, 26, 23, page (6254-6265)
Publication Publié, 2020-12-01
Article révisé par les pairs
| Résumé : | Invasive lobular carcinoma (ILC) represents the second most common histologic breast cancer subtype after invasive ductal carcinoma (IDC). While primary ILC has been extensively studied, metastatic ILC has been poorly characterized at the genomic and immune level. |
